Protease resistant interferon beta mutants
First Claim
Patent Images
1. A modified interferon beta (IFN beta) cytokine, wherein said modified IFN beta cytokine differs from an unmodified IFN beta cytokine by two amino acid substitutionswherein said unmodified IFN beta cytokine comprises the amino acid sequence of SEQ ID NO:
- 196, or comprises a polypeptide with anti-proliferative activity having an amino acid sequence at least 95% identical to SEQ ID NO;
196said two amino acid substitutions being either;
(a) substitution of the 5th and 108th positions in SEQ ID NO;
196, or of the corresponding positions in the unmodified IFN beta cytokine comprising a polypeptide with anti-proliferative activity having an amino acid sequence at least 95% identical to SEQ ID NO;
196, with aspartic acid and serine, respectively;
or(b) substitution of the 6th and 108th positions in SEQ ID NO;
196, or of the corresponding positions in the unmodified IFN beta cytokine comprising a polypeptide with anti-proliferative activity having an amino acid sequence at least 95% identical to SEQ ID NO;
196, with glutamine and serine, respectively,and wherein said two amino acid substitutions confer increased resistance to proteolysis over the unmodified IFN beta cytokine.
4 Assignments
0 Petitions
Accused Products
Abstract
Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.
91 Citations
11 Claims
-
1. A modified interferon beta (IFN beta) cytokine, wherein said modified IFN beta cytokine differs from an unmodified IFN beta cytokine by two amino acid substitutions
wherein said unmodified IFN beta cytokine comprises the amino acid sequence of SEQ ID NO: - 196, or comprises a polypeptide with anti-proliferative activity having an amino acid sequence at least 95% identical to SEQ ID NO;
196said two amino acid substitutions being either; (a) substitution of the 5th and 108th positions in SEQ ID NO;
196, or of the corresponding positions in the unmodified IFN beta cytokine comprising a polypeptide with anti-proliferative activity having an amino acid sequence at least 95% identical to SEQ ID NO;
196, with aspartic acid and serine, respectively;
or(b) substitution of the 6th and 108th positions in SEQ ID NO;
196, or of the corresponding positions in the unmodified IFN beta cytokine comprising a polypeptide with anti-proliferative activity having an amino acid sequence at least 95% identical to SEQ ID NO;
196, with glutamine and serine, respectively,and wherein said two amino acid substitutions confer increased resistance to proteolysis over the unmodified IFN beta cytokine. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- 196, or comprises a polypeptide with anti-proliferative activity having an amino acid sequence at least 95% identical to SEQ ID NO;
Specification